Here, we provide evidence that HDAC and Chk1 inhibitors show strong synergistic interaction in NSCLC cells, providing the foundation for future clinical translation with HDACis and Chk1 inhibitors that are currently in clinical studies for anticancer therapy. Here, CHEK1 is linked to non-small cell lung carcinoma.